Untargeted metabolomics analysis of esophageal squamous cell cancer progression

Tao Yang*, Ruting Hui, Jessica Nouws, Maor Sauler, Tianyang Zeng and Qingchen Wu*

Abstract
90% of esophageal cancer are esophageal squamous cell carcinoma (ESCC) and ESCC has a very poor prognosis and high mortality. Nevertheless, the key metabolic pathways associated with ESCC progression haven’t been revealed yet. Metabolomics has become a new platform for biomarker discovery over recent years. We aim to elucidate dominantly metabolic pathway in all ESCC tumor/node/metastasis (TNM) stages and adjacent cancerous tissues. We collected 60 postoperative esophageal tissues and 15 normal tissues adjacent to the tumor, then performed Liquid Chromatography with tandem mass spectrometry (LC–MS/MS) analyses. The metabolites data was analyzed with metabolites differential and correlational expression heatmap according to stage I vs. con., stage I vs. stage II, stage II vs. stage III, and stage III vs. stage IV respectively. Metabolic pathways were acquired by Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database. The metabolic pathway related genes were obtained via Gene Set Enrichment Analysis (GSEA). mRNA expression of ESCC metabolic pathway genes was detected by two public datasets: gene expression data series (GSE)23400 and The Cancer Genome Atlas (TCGA). Receiver operating characteristic curve (ROC) analysis is applied to metabolic pathway genes. 712 metabolites were identified in total. Glycerophospholipid metabolism was significantly distinct in ESCC progression. 16 genes of 77 genes of glycerophospholipid metabolism mRNA expression has differential significance between ESCC and normal controls. Phosphatidylserine synthase 1 (PTDSS1) and Lysophosphatidylcholine Acyltransferase1 (LPCAT1) had a good diagnostic value with Area under the ROC Curve (AUC) > 0.9 using ROC analysis. In this study, we identified glycerophospholipid metabolism could be a potential therapeutic target of ESCC progression.

Keywords: Esophageal squamous cell carcinoma, Metabolomics, Glycerophospholipid metabolism, PTDSS1, LPCAT1

Background
Esophageal cancer is the sixth leading cause of cancer deaths and one of the poorly understood cancers in the world [1–3]. Approximately, 90% of esophageal cancer is esophageal squamous cell carcinoma (ESCC) [4, 5]. ESCC has a very poor prognosis and high mortality [6], in part because ESCC is usually detected by enhanced thoracic computerized tomography (CT) and gastroscopy at late disease stages.

Metabolomics has become a new platform for biomarker discovery over recent years [7, 8]. Metabolic profiling of Liquid Chromatography with tandem mass spectrometry (LC–MS/MS) can be used to measure multiple metabolic changes simultaneously during pathological processes and identify the dynamic metabolic response of vital intermediary biochemical pathways [9–11]. Metabolomics detection has been applied for a
range of cancers, including esophageal cancer [12–14], brain [15], gastric [16], breast [17], bladder [18], lung [19], and thyroid [20]. Zhu et al. utilized LC–MS/MS to ESCC patients metabolomics via plasma and found eight metabolites panel can be as potential diagnostic biomarkers and indoleacrylic acid, Lysophosphatidylcholine (LPC) (20:5), and Lysophosphatidylethanolamine (LPE) (20:4) were related to the ESCC progression [12]. Toku­naga et al. used capillary electrophoresis time-of-flight mass spectrometry to esophageal cancer and found tri­carboxylic acid cycle activity downregulation in pT3-4 compared to pT1-2 [13]. Chen et al. found tryptophan, formylkynurenine, kynurenine and indoleamine 2,3-diox­gyenase 1 as potential therapeutic targets for ESCC through LC–MS/MS [14]. However, there are no studies exploring all tumor/node/metastasis (TNM) stages metabolic features via ESCC cancerous tissues, thus the key metabolic pathways in ESCC progression haven’t been revealed yet.

This study aimed to determine distinguished metabolites and metabolic pathways for ESCC progression. We use the ultra-high-performance LC–MS/MS analysis of all ESCC TNM stages and normal tissues to the tumor to elucidate the aberrant metabolic pathways and to provide insights into ESCC progression.

Methods
Patients and clinical characteristics
We collected a total of 75 esophageal tissues, including 15 samples of esophageal squamous cell cancer (ESCC) TNM stage I, 15 samples of ESCC TNM stage II, 15 samples of ESCC TNM stage III, 15 samples of ESCC TNM stage IV, and 15 samples of normal tissues adjacent to the tumor in this study. All esophageal samples were from the Frist Affiliated Hospital of Chongqing Medical University, China, from January 2010 to December 2019. The characteristics of these patients were shown in Table 1. The patients were diagnosed with ESCC by preoperative gastroscopy and subsequently recruited for the study. The esophageal tissues were acquired during the gastroscopic biopsy or surgery and were applied for pathologic biopsy. The tumor segments enrolled meet the following criteria: viable tumor nuclei > 80%, total cellularity > 50%, and necrosis < 20% [21, 22]. Normal tissues adjacent to the tumor were acquired by other 15 ESCC patients, all the patients had no illness of esophagitis, acid reflux, or gastritis, and no patients received the chemora­diation therapy before the surgery. All included patients signed informed consent before they participated in the study. The study was implemented in terms of the Declaration of Helsinki, and the study was approved by the Ethics Committee of the First Affiliated Hospital of Chongqing Medical University. All tissue samples were immediately stored at frozen.

Sample preparation and extraction
We performed sample preparation and extraction as previously described [23]. We weighed 25 mg of the sample in an EP tube and added 500 μL of extraction solution (acetonitrile: methanol: water = 2:2:1, a standard internal mixture with isotope labeling). After vortexing for 30 s, we homogenized the samples at 35 Hz for 4 min and

| Characteristics | Esophageal squamous cell carcinoma TNM Stage |
|-----------------|---------------------------------------------|
|                 | TNM Stage I (N = 15) | TNM Stage II (N = 15) | TNM Stage III (N = 15) | TNM Stage IV (N = 15) | Adjacent cancerous tissues (N = 15) |
| Age             |                              |                          |                          |                          |                                  |
| < 65—no. (%)    | 6 (40.0)                     | 5 (33.3)                 | 9 (60.0)                 | 7 (46.7)                 | 11 (73.3)                        |
| ≥ 65—no. (%)    | 9 (60.0)                     | 10 (66.7)                | 6 (40.0)                 | 8 (53.3)                 | 4 (26.7)                         |
| Genders         |                              |                          |                          |                          |                                  |
| Female—no. (%)  | 3 (20.0)                     | 4 (26.7)                 | 1 (6.7)                  | 2 (13.3)                 | 5 (33.3)                         |
| Male—no. (%)    | 12 (80.0)                    | 11 (73.3)                | 14 (93.3)                | 13 (86.7)                | 10 (66.7)                        |
| Body-mass index |                              |                          |                          |                          |                                  |
| Median (IQR)    | 20.8 (19.3–22.5)             | 20.3 (18.2–22.4)         | 19.2 (18.2–20.6)         | 18.6 (17.6–19.2)         | 21.3 (19.9–23.2)                 |

Lt: lower thoracic esophagus, Mt: middle thoracic esophagus, Ut: upper thoracic esophagus

Tumor location was classified according to the Union for International Cancer Control Tumor, Node, Metastasis cancer staging system (ninth edition).
to convert the original data into mzXML for LC–MS/MS analyses were performed using a UHPLC system (Vanquish, Thermo Fisher Scientific) and a UPLC BEH Amide column (2.1 mm × 100 mm, 1.7 μm) combined with a Q Exactive HFX mass spectrometer (Orbitrap MS, Thermo). The mobile phase consists of 25 mmol/L ammonium hydroxide aqueous solution (pH = 9.75) (A) and acetonic acid (B). The analysis was performed with an elution gradient as follows: 0–0.5 min, 95% B; m/z 0.5–7.0 min, 95–65% B; 7.0–8.0 min, 65–40% B; 8.0–9.0 min, 40% B; 9.0–9.1 min, 40–95% B; 9.1–12.0 min, 95% B. The column temperature was 25 °C. The temperature of the auto-sampler was 4 °C, and the injection volume was 3 μL. The QE HFX mass spectrometer was used because it can acquire MS/MS spectra in information dependent acquisition (IDA) mode under the control of acquisition software (Xcalibur, Thermo). In this mode, the acquisition software continuously evaluates the full scan MS spectrum. The ESI source conditions were set as follows: sheath gas flow rate was 50 Arb, the auxiliary gas flow rate was 10 Arb, the capillary temperature was 320 °C, full MS resolution was 60,000, MS/MS resolution was 7500, collision energy was 10/30/in NCE It is 60 in the mode, and the spraying voltage was 3.5 kV (positive) or −3.2 kV (negative).

Qualitative and quantitative analysis of metabolites
We used proteowizard (http://proteowizard.sourceforge.net/) [24] to convert the original data into mzXML format and used an internal program for processing, which was developed using R and based on package XCMS (version 3.7.1) for peak detection, extraction, alignment, and integration. Then the internal mass-spectrometry 2 (MS2) database (BiotreeDB) was applied to metabolite annotation. The cutoff value of the annotation was set to 0.3.

Differentially expressed metabolites selection
In this study, principal component analysis (PCA) and orthogonal projection to least squares discriminant analysis (OPLS-DA) were utilized to simplify the metabolomic data. Therefore, after mean-centering and scaling, the UHPLC data were set to default unit variance, multivariate statistical analysis [25–27] was conducted via SIMCA-P version 16.0 software package (Umetrics Umeå, Sweden). First, we performed unsupervised PCA to observe the inner clusters and find apparent outliers. Then, supervised OPLS-DA was used to distinguish the ESCC samples from the adjacent normal controls visually. The OPLS-DA model eliminates variability unrelated to class separation. The quality and reliability of the model were evaluated by the parameters R²X, R²Y and Q². R²X and R²Y represent the explained data change and R²X indicates the goodness of the fit, R²Y indicates goodness of prediction, while Q² is a sevenfold cross-validation parameter and estimates the predictive ability, with aggregate (cum) values of R2X, R2Y and Q2 equating to ~1 showing a valid model. The cumulative value of the total explained value R2X, R2Y and the predictable change of Q2 suggest that the modeling is correct. To prevent over-fitting, a permutation test (n = 200) in the SIMCA-P software package was applied to the OPLS-DA model [28, 29]. Based on the variable importance of the prediction (VIP) threshold from the OPLS-DA model, the metabolites responsible for ESCC differential from adjacent normal esophageal metabolites can be identified. The Mev (MultiExperiment Viewer) 4.8 software was used to execute one-way ANOVA with standard Bonferroni correction to correct the resultant p values for each metabolite in all cross-comparisons. By VIP > 1.0 and adjust. p value (pFDR)<0.05 (confidence level), all ESCC TNM stages was screened for significantly different metabolites when compared with the adjacent normal esophagus[30]. The heatmap package and corrplot package in R 3.6.3 were used to draw heatmap and correlation matrix among ESCC TNM stage I vs. con., stage I vs. stage II, stage II vs. stage III, and stage III vs. stage IV [31, 32].

Metabolic pathway enrichment and pathway related-genomes analysis
According to the Kyoto Encyclopedia of Genes and Genomes (KEGG) metabolites compounds database [33], we annotated verified metabolites of ESCC TNM stage I vs. con., stage I vs. stage II, stage II vs. stage III, stage III vs. stage IV and then matched the annotated metabolites with the KEGG pathway database. We fed the most significantly regulated metabolite pathway into gene set enrichment analysis (GSEA) [34]. We next analyzed the metabolic pathway genes mRNA expression between ESCC and normal esophageal tissues in public datasets: gene expression data series (GSE)23400 and The Cancer Genome Atlas (TCGA) [35, 36]. Receiver operating characteristic (ROC) curves applied to assess the ESCC progression predictive value by GSE23400 dataset [37].
Results

Patients' characteristics

From January 2010 through December 2019, 75 esophageal tissues were collected including esophageal squamous cell carcinoma (ESCC) and normal tissues adjacent to the tumor. Compared with either ESCC tumor/node/metastasis (TNM) stages and normal controls, more than 70% ESCC patients were male, almost 80% ESCC located at middle and lower esophagus. 65% ESCC Stage II patients were older than 65, and ESCC Stage IV patients had lowest BMI among all groups (IQR, 17.6–19.2). Characteristics of patients see Table 1.

Metabolic profiles of ESCC and normal esophageal tissues

To assess all ESCC TNM stages and adjacent cancerous tissues metabolic profiles, we measured esophageal tissues via LC–MS/MS. Finally, 712 metabolites over 75 classes were identified, including 145 Glycerophospholipids, 124 Carboxylic acids and (its) derivatives, and 84 Fatty Acyls et al. (Additional file 1 Identified Metabolites: Table S1). Phosphatidylethanolamine (PE) and phosphatidylcholine (PC) were mostly Glycerophospholipids species. The data that support the findings of this study have been deposited into MetaboLights of EMBL-EBI with MTBLS3579 [38].

Multivariate statistics analysis

Principle component analysis (PCA), and orthogonal partial least squares discriminant analysis (OPLS-DA) as data mining methods are used to build multivariate models to discriminate metabolomic profiling among ESCC TNM stages and adjacent cancerous tissues [39]. PCA score plots showed a clear trend of group clusters between the ESCC patients and normal controls (Additional file 1 PCA: Fig. S1). Additionally, to exclude variables with smaller correlations, a supervised OPLS-DA classification model using one PLS component and one orthogonal component was established. The OPLS-DA score plots obtained even clearer class discrimination (Fig. 1A). Goodness of fit (R2 X and R2Y) of ESCC TNM stages versus controls were 0.479 and 0.912, and Q2 of OPLS-DA was 0.815. These results indicated 712 metabolites were well explained by OPLS-DA models. To validate the OPLS-DA models, random permutation tests with 200 permutations were performed (Additional file 1: Validation plots. Fig. S2). Decrease of Q2 and R2 was observed along with the decrease of X-axis value, suggesting the model did not overfit. The PCA and OPLS-DA plots showed good discrimination between all ESCC TNM stages and normal controls.

Differential metabolites screening

To differentiate specific metabolites among all ESCC TNM stages vs. adjacent normal controls, OPLS-DA results were used to screen all metabolites with significant differences. The Variable Importance in Projection (VIP) obtained from OPLS-DA reflects both the loading weights for each sample and the metabolite of the response explained by this sample and can be used for metabolite selection. In this study, the metabolites concentration VIP value (VIP > 1) combined with the metabolite's concentration adjust $p$-value ($pFDR < 0.05$) was used to screen the crucial metabolites. As a result, 145 metabolites had significant differences among all ESCC TNM stages vs. Con.; the ESCC TNM stage I vs. Con. group had 151 metabolites with significant differences; the ESCC TNM stage I vs. stage II group had 100 metabolites with significant differences; the ESCC TNM stage II vs. stage III group had 144 metabolites with significant differences; and the ESCC TNM stage III vs. stage IV group had 120 metabolites with significant differences. Heatmaps were plotted using z-score among all ESCC TNM groups and normal control group.

Metabolite's correlation analysis in ESCC progression

Pearson correlation coefficient analysis was applied for metabolite-metabolite correlation analysis via z-score in all ESCC TNM Stages vs. Con. This analysis identified metabolites that associated with each other in esophageal carcinoma and normal controls. Specifically, we compared metabolite correlations between each pair of samples (stage I vs. con., stage I vs. stage II, stage II vs. stage III, and stage III vs. stage IV), and the metabolite-metabolite correlations of these three sample combinations showed unique profiles. Metabolites with correlation coefficients $p < 0.1$ was identified as significantly correlation (Fig. 2A–D).

KEGG pathway related to ESCC Progression

To validate ESCC progression related metabolic pathway, significantly differential metabolites in all ESCC TNM stage vs. Con were retrieved from the KEGG compound database. The results of the KEGG pathway enrichment analysis were displayed 16 pathways in either ESCC TNM stages and adjacent normal control via adjust $p$-value ($pFDR < 0.05$), metabolites count, and enrichment ratio. Among all ESCC TNM stage vs. Con. groups, the Glycerophospholipid metabolism pathway was the most significantly distinct metabolic pathway (Fig. 2E–H).
**Glycerophospholipid metabolism genes analysis**

We obtained the gene set of Glycerophospholipid metabolism genes from the GSEA. A total of 77 genes were retrieved by Glycerophospholipid metabolism (Additional file 1 mRNA Expressions of Glycerophospholipid Metabolism Genes: Table S2). Moreover, we analyzed the 77 genes mRNA expression in normal esophageal tissues and all stages of ESCC tissues in
GSE23400 and TCGA dataset and found 16 genes had significantly differential expression (Fig. 3A–Q). Then 16 significantly differential genes of Glycerophospholipid metabolism were performed ROC test from GSE23400. Phosphatidylserine Synthase 1 (PTDSS1) (AUC = 0.980) and Lysophosphatidylcholine Acyltransferase 1 (LPCAT1) (AUC = 0.914) showed a good prediction of ESCC in Fig. 3R.

Discussion

For metabolic pathways of esophageal squamous cell cancer (ESCC) were still unclear, we embarked on a metabolomics study. In this study, we found 712 metabolites in all tumor/node/metastasis (TNM) ESCC and adjacent normal tissues, in which were 145 glycerophospholipid. Moreover, we found glycerophospholipid metabolism was dominant in all TNM ESCC stages via Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. Furthermore, glycerophospholipid metabolism was associated with 77 genes, in which 16 genes were linked to ESCC. In addition, we generated a receiver operating characteristic curve (ROC) curve for each 16 significantly differential mRNA expression genes in ESCC and reported the Area under the Curve (AUC) for each gene. Phosphatidylserine Synthase 1 (PTDSS1) and Lysophosphatidylcholine Acyltransferase 1 (LPCAT1) had a good diagnostic value with AUC > 0.9. These findings suggested glycerophospholipid metabolism was related to ESCC progression.

In recent years, metabolomic based approaches have been recognized as an emerging tool to discover products of cellular biochemical reactions that fuel cell proliferation in a variety of malignancies. Several studies [40–42] have found distinct differences in the metabolic profile of patients with cancers and related disorders. Pandey et al. utilized Nuclear Magnetic Resonance (NMR) metabolomes to distinguish brain tumors in vitro and vivo and identified Cysteine metabolism as a crucial marker in brain cancer aggressiveness [40]. Jing et al. employed liquid chromatography–tandem mass spectrometry (LC–MS/MS) to detect 84 gastric cancer patients and 82 gastric ulcer patients’ plasma samples, and found five differential amino acids, glutamine, ornithine, histidine, arginine, and tryptophan, were identified for discerning between gastric cancer and gastric ulcer [41]. Barberini et al. examined pre-treatment plasma samples from 66 adult patients with any lymphoma sub-type and 96 frequency-matched population controls and found fatty acids were mostly represented in multiple myeloma and Hodgkin lymphoma patients [42]. Here, we employed LC–MS/MS to detect 75 samples of all TNM stages ESCC and normal tissues adjacent to the tumor metabolomes and identified 712 metabolites and the dominant metabolites were 145 glycerophospholipid. We thus brought insight into how metabolites were involved in ESCC, and these findings contributed new insights for researchers to understand the role of metabolites in ESCC.

Glycerophospholipid metabolism is currently understood as most relevant to cancer development and progression [43–46]. Major glycerophospholipids (GPLs) in the cell include phosphatidylserine (PS), Phosphatidylethanolamine (PE), phosphatidylcholine (PC), phosphatidylinositol (PI), phosphatidic acid (PA), phosphatidylglycerol (PG), and cardiolipin (CL) [47]. Here, PC and PE were identified as the two most abundant GPLs in all ESCC TNM stages and normal control tissues. PE was a critical precursor for PC. Tsigelny et al. used metabolomics to study early and late stages of bladder cancer, and they found that glycerophospholipid metabolism was related to late-stage bladder cancer [44]. Ridgway reported phosphatidylcholine and choline metabolites involved in cancer cells signaling or growth pathways and contribute to both proliferative growth and programmed cell death [45]. Uchiyama et al. elucidated PC species played an important role in the mechanism of cancer invasion using imaging mass spectrometry [46]. In this study, LC–MS/MS identified glycerophospholipid metabolism was a cofactor that related to ESCC oncogenesis and progression (Fig. 4).

Metabolites of glycerophospholipid metabolism, phosphatidylethanolamine (PE) and phosphatidylcholine (PC), were consistent from stage I to stage IV of ESCC, thus related to ESCC progression. PTDSS1 encodes phosphatidylserine synthase 1 to catalyze a base-exchange reaction in which the polar head group of PE or PC is replaced by l-serine. Zhu et al. and Chen et al. found PE and PC were associated with ESCC progression and were potential therapeutic target [12, 14]. You-Tyun et al. found that phosphatidylserine synthase 1 (PTDSS1) was an oncogene and a potential therapeutic target for lung adenocarcinoma [48]. Lysophosphatidylcholine Acyltransferase1 (LPCAT1) encodes Lysophosphatidylcholine acyltransferase 1 to catalyze the conversion of lysophosphatidylcholine (1-acyl-sn-glycero-3-phosphocholine) into PC. Several studies have shown that in
Fig. 2 (See legend on previous page.)
many solid tumors chemoresistance, tumor aggressiveness and worsened survival correlated with LPCAT1 [49–51]. Here, we found lysophosphatidylcholine was abundant in all ESCC TNM stages vs. Con groups. Taken together, glycerophospholipid metabolism was potential diagnosis, severity assessment and therapeutic options of ESCC progression. However, we also realized that this study has a few limitations. The major weakness is this study only contains Asian population. Thus, the predictive values of the glycerophospholipid metabolism for ESCC should also be
replicated in other populations and ethnic groups. Additionally, metabolites changes are informative but do not always reflect protein concentration or function. Collectively, the most advantage of this study is that we investigate metabolome among all TNM stages ESCC versus adjacent normal esophagus.

**Conclusions**

Taken together, glycerophospholipid metabolism promotes ESCC progression, and could be a potential therapeutic target for ESCC progression.

**Abbreviations**

ESCC: Esophageal squamous cell carcinoma; LC–MS-MS: Liquid chromatography with tandem mass spectrometry; QC: Quality control; IDA: Information-related acquisition; PCA: Principal component analysis; OPLS-DA: Orthogonal projection to least squares discriminant analysis; VIP: Variable importance of the prediction; ROC: Receiver operating characteristic; GPLs: Glycerophospholipids; PS: Phosphatidylserine; PE: Phosphatidylethanolamine; PC: Phosphatidylcholine; PI: Phosphatidylinositol; PA: Phosphatidic acid; PG: Phosphatidylglycerol; CL: Cardiolipin; PTDSS1: Phosphatidylserine synthase 1; LPCAT1: Lysophosphatidylcholine acyltransferase1.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12967-022-03311-z.

**Acknowledgements**

We would like to thank Shanghai Biotree Biotechnology for the LC–MS/MS.

**Authors’ contributions**

QCW designed the study, outlined the manuscript, and conceived the project. TY performed patients’ samples collection, data analysis, drafted the manuscript with additional input from all authors, and wrote the manuscript. RTH and JN performed the data analysis and wrote the manuscript. MS and TYZ contributed to the literature search and data collection and suggested additional experiments. All authors read and approved the final manuscript.

**Funding**

This study was supported by funding from the Chongqing Natural Science Foundation (Grant Number: cstc2018jcyjX0245). This funding was involved in the samples collection, data analysis, and interpretation of data, in the writing of the report; and in the decision to submit the paper for publication.

**Availability of data and materials**

The data that support the findings of this study have been deposited into MetaboLights of EMBL-EBI with MTBLS3579.

---

**Fig. 4** Diagram of glycerophospholipid metabolism in ESCC. Glycerophospholipid metabolic pathway for the biosynthesis of glycerophosphate from lactate and glutamine under tumor cells starvation.
Declarations

Ethics approval and consent to participate
The study was approved by the Ethics Committee of the First Affiliated Hospital of Chongqing Medical University (IRB protocol: 2020-64).

Consent for publication
Not applicable.

Competing interests
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Author details
1. Huang X, Zhou X, Hu Q, Sun B, Deng M, Qi X, Lü M. Advances in esophageal cancer: a new perspective on pathogenesis associated with long non-coding RNAs. Cancer Lett. 2018;413:94–101.

References

1. Huang X, Zhou X, Hu Q, Sun B, Deng M, Qi X, Lü M. Advances in esophageal cancer: a new perspective on pathogenesis associated with long non-coding RNAs. Cancer Lett. 2018;413:94–101.

2. Li D, Zhang L, Liu Y, Sun H, Onwuka JU, Zhao Z, Tian W, Xu J, Zhao Y, Xu H. Specific DNA methylation markers in the diagnosis and prognosis of esophageal cancer. Aging. 2019;11(23):11640–50.

3. Li B, Hong P, Zheng CC, Dai W, Chen WY, Rabinowitz JD. Metabolomics and isotope tracing. Cell. 2017;1641:229–58.

4. Tramontano AC, Chen Y, Watson TR, Eckel A, Hur C, Kong CY. Esophageal cancer treatment costs by phase of care and treatment modality, 2000–2013. Cancer Med. 2019;8(11):5158–72.

5. Song Y, Li L, Ou Y, Gao Z, Li E, Li X, Zhang W, Wang J, Xu L, Zhou Y, et al. Identification of genomic alterations in esophageal squamous cell cancer. Nature. 2014;509(7500):617–21.

6. Baba Y, Yoshida N, Kinoshita K, Iwatsuki M, Yamashita YI, Chikamoto A, Watanabe M, Baba H. Clinical and prognostic features of patients with esophageal cancer and multiple primary cancers: a retrospective single-institution study. Ann Surg. 2018;267(3):478–83.

7. Jiang C, Chen L, Rabinowitz JD. Metabolomics and isotope tracing. Cell. 2018;173(4):822–37.

8. Rinschen MM, Ivanisevic J, Giera M, Siuzdak G. Identification of bioactive metabolites using activity metabolomics. Nat Rev Mol Cell Biol. 2019;20(6):353–67.

9. Johnson CH, Ivanisevic J, Siuzdak G. Metabolomics: beyond biomarkers and towards mechanisms. Nat Rev Mol Cell Biol. 2016;17(7):451–9.

10. Amberger A, Riffke B, Schlatterbeck G, Ross A, Senn H, Dieteler F, Keck M. NMR and MS methods for metabolomics. Methods Mol Biol. 2017;1641:229–58.

11. Roberts LD, Souza AL, Gersztew RB, Clish CB. Targeted metabolomics. Curr Protoc Mol Biol. 2012;Chapter 30:Unit 30.32.31–24.

12. Zhu Z, Qi Z, Zhang J, Xue WH, Li LF, Shen ZB, Li ZY, Yuan YL, Wang WB, Zhao J. Untargeted metabolomics analysis of esophageal squamous cell carcinoma discovers dysregulated metabolic pathways and potential diagnostic biomarkers. J Cancer. 2020;11(13):3944–54.

13. Tokunaga M, Kami K, Ozawa S, Oguma J, Kazuno A, Miyachi H, Ohashi Y, Kusuhara H, Terashima M. Metabolome analysis of esophageal cancer tissues using capillary electrophoresis-time-of-flight mass spectrometry. Int J Oncol. 2018;52(6):1947–58.

14. Chen Z, Dai Y, Huang X, Chen K, Gao Y, Li N, Wang D, Chen A, Yang Q, Hong Y, et al. Combined metabolic analysis of plasma and tissue reveals a prognostic risk score system and metabolic dysregulation in esophageal squamous cell carcinoma. Front Oncol. 2020;10:1545.

15. Wu Y, Hu L, Liang Y, Li J, Wang K, Chen X, Meng H, Guan X, Yang K, Bai Y. Up-regulation of IncRNA CAS9 promotes esophageal squamous cell carcinoma growth by negatively regulating PDCD4 expression through EZH2. Mol Cancer. 2017;16(1):150.

16. Chan AW, Gill RS, Schiller D, Sawyer MB. Potential role of metabolomics in diagnosis and surveillance of gastric cancer. World J Gastroenterol. 2014;20(36):12874–82.

17. Kwa M, Plottel CS, Blaser MJ, Adams S. The intestinal microbiome and estrogen receptor-positive female breast cancer. J Natl Cancer Inst. 2016. https://doi.org/10.1093/jnci/djw029.

18. Sahu D, Lotan Y, Wittmann B, Neri B, Hansel DE. Metabolism analysis reveals distinct profiles of nonmuscle-invasive and muscle-invasive bladder cancer. Cancer Med. 2017;6(9):2106–20.

19. Noreldeen HAA, Liu X, Xu G. Metabolomics of lung cancer: analytical platforms and their applications. J Sep Sci. 2020;43(1):120–33.

20. Abooshahab R, Ghomami M, Sanoe M, Azizi F, Hedaya M. Advances in metabolomics of thyroid cancer diagnosis and metabolic regulation. Endocrinol. 2019;65(1):1–14.

21. Dou Y, Kawaiwa EA, Cui Z, Dritsken MA, Huang C, Blumenberg L, Karpova A, Petyuk VA, Savage SR, Sapathy S, et al. Proteogenomic characterization of endometrial carcinoma. Cell. 2020;180(4):729-748.e726.

22. Jin X, Liu L, Wu J, Jia L, Wang F, Shi M, Lu H, Liu J, et al. A multi-omics study delineates new molecular features and therapeutic targets for esophageal squamous cell carcinoma. Clin Transl Med. 2021;11(9):e538.

23. Yuan M, Kremer DM, Huang H, Breitkopf SB, Ben-Sahra I, Manning BD, Lyons SJ, Asara JM. Ex vivo and in vivo stable isotope labelling of central carbon metabolism and related pathways with analysis by LC-MS/MS. Nat Protoc. 2019;14(2):313–30.

24. Chambers MC, Maclean B, Burke R, Amodei D, Ruderman DL, Neumann S, Gatto L, Fischer B, Pratt B, Egerton J, et al. A cross-platform toolkit for mass spectrometry and proteomics. Nat Biotechnol. 2012;30(10):918–20.

25. Davis VW, Schiller DE, Eunich D, Bathe OF, Sawyer MB. Pancreatic ductal adenocarcinoma is associated with a distinct urinary metabolic signature. Ann Surg Oncol. 2013;20(Suppl 3):S543–421.

26. Alonsoz S, Tisunime J, Wallace J, Dufton MJ, Parkinson JA, Young LC, Clements CJ, Park JK, Jeon JW, Ferro VA, et al. Metabolomic profiling of the sympathetic effects of melatonin in combination with cisplatin on ovarian cancer cells. Metabolites. 2017;7(2):14.

27. Wu X, Zhu JC, Zhang Y, Yu WM, Rong XL, Feng YF. Lipidomics study of plasma phospholipid metabolism in early type 2 diabetes rats with isogenic preaption Huang-Qian-San intervention by UPLC/Q-TOF-MS and correlation coefficient. Chem Biol Interact. 2016;256:71–84.

28. Triba MN, Le Moyec AL, Amathieu R, Goossens C, Bouchemal N, Nahon P, Rutledge DN, Savarin P, PLS/OPLS models in metabolomics: the impact of permutation of data rows on the fold-cross-validation quality parameters. Mol Biosyst. 2011;15(1):13–09.

29. Paskinait K, Fesuvaranathan K, Hong Y, Ho PC, Mahendran R, Ramanee Mani L, Chiong E, Chan EC. Urinary metabotyping of bladder cancer using two-dimensional gas chromatography time-of-flight mass spectrometry. J Proteome Res. 2013;12(9):3865–73.

30. Sui W, Gan Q, Liu F, Ou M, Wang B, Liao S, Lai L, Chen H, Yang M, Dai Y. Dynamic metabolomics study of the bile acid pathway during perioperative primary hepatic carcinoma following liver transplantation. Ann Transplant. 2020;25: e921844.

31. Cheng M, An S, Li J. CDKN2B-AS may indirectly regulate cancer disease-associated genes via targeting miR-29a. Gene. 2017;629:101–7.

32. Cao H, Zhang Y, Chu Z, Zhao B, Wang H, An L. MAP-1B; PAC-2 and AHCYL1 are regulated by miR-34A/B/C and miR-449 in neuroplasticity following traumatic spinal cord injury in rats: preliminary explorative results from microarray data. Mol Med Rep. 2019;20(4):3011–8.

33. Zhang X, Xu L, Shen J, Cao B, Cheng T, Zhao T, Liu X, Zhang H. Metabolic signatures of esophageal cancer: NMR-based metabolomics and UHPLC-based focused metabolomics of blood serum. Biochim Biophys Acta. 2013;1832(8):1207–17.

34. Cheng J, Yamamoto M, Xia J. MetaboAnalyser 2.0: from raw spectra to biological insights. Metabolites. 2019;9(3):57.
36. Toro-Dominguez D, Martorell-Marugán J, López-Dominguez R, García-Moreno A, González-Rumayor V, Alarcón-Riquelme ME, Carmona-Sáez P. ImaGEO: integrative gene expression meta-analysis from GEO database. Bioinformatics. 2019;35(5):880–2.

37. Chang YT, Huang CS, Yao CT, Su SL, Teng HJ, Chou HL, Chou YC, Chen KH, Shih YW, Lu CY, et al. Gene expression profile of peripheral blood in colorectal cancer. World J Gastroenterol. 2014;20(39):14463–71.

38. Haug K, Cochrane K, Mainala VC, Williams M, Chang J, Jayaseelan KY, O’Donovan C. MetaboLights: a resource evolving in response to the needs of its scientific community. Nucleic Acids Res. 2020;48(D1):D440–d444.

39. Zhao S, Liu H, Su Z, Khoo C, Gu L. Identifying cranberry juice consumers with predictive OPLS-DA models of plasma metabolome and validation of cranberry juice intake biomarkers in a double-blinded, randomized, Placebo-controlled, cross-over study. Mol Nutr Food Res. 2020;64(11). e1901242.

40. Pandey R, Caffisch L, Lodi A, Brenner AJ, Tiziani S. Metabonomic signature of brain cancer. Mol Carcinog. 2017;56(11):2355–71.

41. Jing F, Hu X, Cao Y, Xu M, Wang Y, Jing Y, Hu X, Gao Y, Zhu Z. Discriminating gastric cancer and gastric ulcer using human plasma amino acid metabolic profile. JUBM Life. 2018;70(6):553–62.

42. Barberini L, Noto A, Fattuoni C, Satta G, Zucca M, Cabras MG, Mura E, Cocco P. The metabolomic profile of lymphoma subtypes: a pilot study. Molecules. 2019;24(13):2367.

43. Phan TK, Bindra GK, Williams SA, Poon IKH, Hulett MD. Combating human pathogens and cancer by targeting phosphoinositides and their metabolism. Trends Pharmacol Sci. 2019;40(11):866–82.

44. Kouznetsova VL, Kim E, Romm EL, Zhu A, Tsigelny IF. Recognition of early and late stages of bladder cancer using metabolites and machine learning. Metabolomics. 2019;15(7):94.

45. Ridgway ND. The role of phosphatidylcholine and choline metabolites to cell proliferation and survival. Crit Rev Biochem Mol Biol. 2013;48(1):20–38.

46. Uchiyama Y, Hayasaka T, Masaki N, Watanabe Y, Masumoto K, Nagata T, Katou F, Setou M. Imaging mass spectrometry distinguished the cancer and stromal regions of oral squamous cell carcinoma by visualizing phosphatidylcholine (16:0/16:1) and phosphatidylcholine (18:1/20:4). Anal Bioanal Chem. 2014;406(5):1307–16.

47. Calzada E, Onguka O, Claypool SM. Phosphatidylethanolamine metabolism in health and disease. Int Rev Cell Mol Biol. 2016;321:29–88.

48. Wang YT, Lin MR, Chen WC, Wu WH, Wang FS. Optimization of a modeling platform to predict oncopgenes from genome-scale metabolic networks of non-small-cell lung cancers. FEBS Open Bio. 2021;11(8):2078–94.

49. Wei C, Dong X, Lu H, Tong F, Chen L, Zhang R, Dong J, Hu Y, Wu G, Dong X. LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating PI3K/AKT/MYC pathway. J Exp Clin Cancer Res. 2019;38(1):95.

50. Bi J, Ichu TA, Zanca C, Yang H, Zhang W, Gu Y, Chowdhry S, Reed A, Ikegami S, Turner KM, et al. Oncogene amplification in growth factor signaling pathways renders cancers dependent on membrane lipid remodeling. Cell Metab. 2019;30(3):525–538.e528.

51. Du Y, Wang Q, Zhang X, Wang X, Qin C, Sheng Z, Yin H, Jiang C, Li J, Xu T. Lysophosphatidylcholine acyltransferase 1 upregulation and concomitant phospholipid alterations in clear cell renal cell carcinoma. J Exp Clin Cancer Res. 2017;36(1):66.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions